Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy

CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. It also binds to the RBC along with the plasma cells in concern, creating a menace in the immunohematology workups and requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Soma, Chowdhry, Mohit, Karna, Prashant, Agrawal, Ankit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983141/
https://www.ncbi.nlm.nih.gov/pubmed/33767552
http://dx.doi.org/10.4103/ajts.AJTS_19_19
_version_ 1783667853286703104
author Agrawal, Soma
Chowdhry, Mohit
Karna, Prashant
Agrawal, Ankit
author_facet Agrawal, Soma
Chowdhry, Mohit
Karna, Prashant
Agrawal, Ankit
author_sort Agrawal, Soma
collection PubMed
description CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. It also binds to the RBC along with the plasma cells in concern, creating a menace in the immunohematology workups and requires the use of dithiothreitol-treated cells to rule out its interference. Appropriate and timely communication with the clinicians about the patient history goes a long way in solving complex looking immunohematology workups.
format Online
Article
Text
id pubmed-7983141
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-79831412021-03-24 Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy Agrawal, Soma Chowdhry, Mohit Karna, Prashant Agrawal, Ankit Asian J Transfus Sci Case Report CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. It also binds to the RBC along with the plasma cells in concern, creating a menace in the immunohematology workups and requires the use of dithiothreitol-treated cells to rule out its interference. Appropriate and timely communication with the clinicians about the patient history goes a long way in solving complex looking immunohematology workups. Wolters Kluwer - Medknow 2020 2020-12-19 /pmc/articles/PMC7983141/ /pubmed/33767552 http://dx.doi.org/10.4103/ajts.AJTS_19_19 Text en Copyright: © 2020 Asian Journal of Transfusion Science http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Agrawal, Soma
Chowdhry, Mohit
Karna, Prashant
Agrawal, Ankit
Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title_full Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title_fullStr Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title_full_unstemmed Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title_short Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
title_sort daratumumab: the perplexity in immunohematology with emerging horizons in myeloma therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983141/
https://www.ncbi.nlm.nih.gov/pubmed/33767552
http://dx.doi.org/10.4103/ajts.AJTS_19_19
work_keys_str_mv AT agrawalsoma daratumumabtheperplexityinimmunohematologywithemerginghorizonsinmyelomatherapy
AT chowdhrymohit daratumumabtheperplexityinimmunohematologywithemerginghorizonsinmyelomatherapy
AT karnaprashant daratumumabtheperplexityinimmunohematologywithemerginghorizonsinmyelomatherapy
AT agrawalankit daratumumabtheperplexityinimmunohematologywithemerginghorizonsinmyelomatherapy

Ejemplares similares